Federal health officials announced Thursday they have initiated conversations with drug manufacturers regarding legislation to implement President Donald Trump’s most-favored-nation pricing proposal.
Chris Klomp, chief counselor for the U.S. Department of Health and Human Services, stated the administration has started briefing pharmaceutical companies on the initiative. The plan would bring American prescription medication prices in line with costs seen in other developed nations worldwide.
The most-favored-nation approach represents the Trump administration’s effort to reduce prescription drug expenses for American consumers by matching international pricing standards.
